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Background:  Intervals  longer  than  recommended  are frequently  encountered  between  doses  of  tick  borne
encephalitis  virus  (TBE)  vaccines  in both  residents  of  and  travelers  to endemic  regions.  In  clinical  practice
the  management  of individuals  with  lapsed  TBE  vaccination  schedules  varies  widely and  has  in  common
that  the  underlying  immunological  evidence  is scarce.
Study purpose  and  methods:  The  aim of this  study  was  to  generate  data  reliable  enough  to derive  practical
recommendations  on how  to  continue  vaccination  with  FSME-IMMUN  in  subjects  with  an  irregular  TBE
vaccination  history.  Antibody  response  to a single  catch-up  dose  of FSME-IMMUN  was  assessed  in 1115
adults  (age  ≥16  years)  and  125  children  (age 6–15  years)  with  irregular  TBE  vaccination  histories.
Results: Subjects  of  all  age  groups  developed  a substantial  increase  in  geometric  mean  antibody  concen-
tration  after  a single  catch-up  TBE vaccination  which  was  consistently  lower  in subjects  with  only  one
previous  TBE  vaccination  compared  to subjects  with  two  or  more  vaccinations.  Overall,  >94%  of  young
adults  and  children,  and >93%  of  elderly  subjects  with  an  irregular  TBE  vaccination  history  achieved
antibody  levels  ≥25  U/ml  irrespective  of the  number  of previous  TBE  vaccinations.
Conclusion:  We  conclude  that  TBE vaccination  of  subjects  with  irregular  vaccination  histories  should  be
continued  as  if the  previous  vaccinations  had  been  administered  in  a regular  manner,  with  the  stage
of  the vaccination  schedule  being  determined  by  the  number  of  previous  vaccinations.  Although  lapsed
vaccination  schedules  may  leave  subjects  temporarily  with  inadequate  protection  against  TBE  infection,
adequate  protection  can quickly  be  re-established  in >93%  of  the  subjects  by  a single  catch-up  dose
of  FSME-IMMUN,  irrespective  of age,  number  of  previous  vaccinations,  and  time  interval  since  the last
2014
vaccination.
©  
. IntroductionTick-borne encephalitis (TBE) is endemic in large areas of Cen-
ral, Northern and Eastern Europe as well as in Central and Northern
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Asia [1,2]. The disease is caused by the TBE virus (TBEV) and is
transmitted by the bite of infected ticks. TBE is associated with
considerable morbidity as well as mortality rates ranging from 0.5
to 2% (Central European strains) up to 40% (Far Eastern strains) in
subjects with CNS involvement [1–3]. There is no causal therapy
available. Vaccination is the most efﬁcient means to prevent the
disease.
FSME-IMMUN (Baxter AG, Vienna, Austria) is an inactivated
whole virus vaccine against TBE. The primary immunization course
consists of 3 vaccinations at day 0, 1–3 months, and 5–12 months
Open access under CC BY-NC-ND license.after the preceding vaccination. A rapid immunization scheme is
available for travelers comprising 2 vaccinations at days 0 and 14,
followed by the regular 3rd dose after 5–12 months. According to
the marketing authorization, the ﬁrst booster should be given not
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ater than 3 years after the third dose. Further booster vaccinations
re recommended in 3- to 5-year intervals, depending on age [4,5].
he overall ﬁeld effectiveness of the TBE vaccine has been estimated
o range between 96% and 99% in regularly vaccinated persons,
owever irregularly vaccinated persons have been shown to have
ower degrees of protection [4,5]. Besides FSME-IMMUN a second
rophylactic TBE vaccine (Encepur®, Novartis Vaccines, Marburg,
ermany) is available in several European countries. Vaccination
chemes are similar for both TBE vaccines. In clinical studies in
dults and children, subjects who received the 3 doses of the
rimary vaccination course with the same brand showed similar
eropositivity rates compared to subjects who received the third
ose of the other brand [6–9]. Clinical practice, as reﬂected by the
ueries of general practitioners and pediatricians to the marketing
uthorization holder (Baxter), has shown that incomplete and/or
rregular vaccination histories are frequently encountered in both
esidents of and travelers to endemic geographies. Guidelines on
ow to proceed with the TBE vaccine FSME-IMMUN in subjects
ith an irregular and/or incomplete TBE vaccination history are
herefore imperative but the body of evidence on the immunolog-
cal effects of irregular TBE vaccination in both adults and children
s scarce [10,11]. Different strategies are followed in current prac-
ice: (1) restart of the basic vaccination course, (2) measurement
f the serum anti-TBE antibody concentration to support the deci-
ion on the further vaccination schedule, or (3) administration of
ne or more catch-up vaccinations followed by continuation of the
ecommended schedule.
The  aim of this study was to generate a data basis reliable
nough to derive practical recommendations on how to continue
accination with FSME-IMMUN in subjects with an irregular TBE
accination history. For this reason, the antibody response to a
ingle catch-up dose of FSME-IMMUN in irregularly vaccinated sub-
ects ≥6 years of age was assessed in an open manner.
. Material and methods
.1.  Study design and population
The  study was conducted from May  1, 2005, to December 31,
006 and was designed in accordance with the Recommendation
n the Planning and Conduct of Post-authorization Observational
tudies issued by the German Federal Institute for Drugs and Med-
cal Devices [12] as a post-authorization multi-center open-label
on-interventional study in individuals with irregularity patterns
f their TBE vaccination histories. The study was  carried out in
ccordance with the Declaration of Helsinki. The study protocol was
eviewed and approved by ﬁve independent ethics committees.
Healthy  subjects ≥6 years of age (for details of the inclu-
ion/exclusion criteria see supplementary data) with an irregular
BE vaccination history as depicted in Table 1 were eligible. Par-
icipation in the study included two visits: At the ﬁrst visit written
nformed consent was obtained. Then a blood sample was  drawn
nd the catch-up vaccination was administered (FSME-IMMUN
unior 0.25 ml  in subjects ≥6 to <16 years of age, FSME-IMMUN
.5 ml  in subjects ≥16 years of age). The second visit was sched-
led 3–12 weeks after the catch-up vaccination to obtain a second
lood sample.
.2.  Study objectives
The  main objectives of the study were (1) to characterize irreg-
larly vaccinated subjects in daily practice with respect to number
nd time intervals of TBE vaccinations, and (2) to determine the
uccess of a single catch-up vaccination with FSME-IMMUN in sub-
ects with an irregular TBE vaccination history by measurement of
BE IgG antibody concentrations in pre- and post-vaccination sera.2 (2014) 2375–2381
2.3. Antibody testing
The  blood samples were tested for TBE IgG antibodies by a
commercially available ELISA (Enzygnost® Anti-FSME-Virus, Dade
Behring, Germany). The threshold was  set to 25 U/ml for puta-
tive seroprotection. All TBE antibody concentrations below 10 U/ml
were set to 9.99 for statistical analysis.
2.4. Statistical analysis
The  data were analyzed by descriptive statistical methods.
Mean ± SD or median ± quantiles were calculated as appropriate.
Point estimates and 95% conﬁdence intervals (CIs) were calculated
for putative seroprotection rates. Geometric mean concentrations
(GMC) with 95% CI and reverse cumulative distribution (RCD) plots
were generated.
2.5.  Safety analysis
Due  to the extensive safety record of FSME-IMMUN vac-
cines [9,13] and the observational design of the study, no active
safety measurements were performed. However, investigators
were instructed to document and report any adverse reaction they
become aware of during the conduct of the study. Safety analy-
sis was  limited to calculating the incidence of reported adverse
reactions.
2.6. Role of the funding source
The study was  designed and funded by Baxter. Baxter employees
RS, AR and BU were responsible for study design, data collection,
data analysis, data interpretation, and writing of the manuscript.
Baxter independent co-authors UM,  UH and RK served as the sci-
entiﬁc advisory committee and were fully involved in the design
of the study, data interpretation, and writing of the manuscript.
UM was  the responsible statistician and conducted the data man-
agement and analysis. The submission for publication was jointly
decided by all authors. The corresponding author had full access to
all data of the study. All study data were available to all authors on
request.
3. Results
3.1. Demographic data
A  total number of 2915 subjects were enrolled in 459 pediatric
and general medical practices throughout Germany whereof 1240
(42.5%; 1115 adults and 125 children) fulﬁlled the criteria for inclu-
sion in this analysis. Demographic attributes and their distribution
in subgroups by number of previous vaccinations and time interval
since the last vaccination are shown for adults in Tables 2a and 2b.
Adult study population: The median age was 34 years in young
adults (16–50 years) and 61 years in the elderly (≥50 years). The
median weight was  82.0 kg in males and 65.4 kg in females. As
shown in Table 2b, 50% of the young adults presented with a mini-
mum time interval between the last vaccination and the catch-up
vaccination of 4.9–7.1 years, depending in the number of previous
vaccinations, and 25% had an interval of at least 8.5–9.0 years. The
respective ﬁgures for the elderly are 4.6–6.0 years (50%) and 7.3–8.8
years (25%). The maximum intervals ranged from 16.5–22.3 (young
adults) and 17.4–23.0 years (elderly).
Pediatric study population: Due to the small sample size (n = 125),
no further age stratiﬁcation was applied. With regard to the
TBE vaccination history, the most prominent group consisted of
R. Schosser et al. / Vaccine 32 (2014) 2375–2381 2377
Table  1
Deﬁnition of irregular TBE vaccination history. The conditions to be met  for inclusion in the study are expressed in Boolean notation: AND = both conditions must apply,
OR = one of both conditions must apply.
Number of
previous
vaccinations
Time interval Conditions to be met for
inclusion  in the analysis
Condition 1 Condition 2 Condition 3 Condition 4
1st  → 2nd vacc. 2nd → 3rd vacc. 3rd vacc. → 1st booster
or booster → booster
Last vacc. → catch-up vacc.
1 N/A N/A N/A ≥123 days 4
2  ≥123 days N/A N/A ≥457 days 1 OR 4
3  ≥123 days ≥457 days N/A ≥1278 days (1 OR 2) AND 4
≥4 ≥123 days ≥457 days ≥1278 days
Table 2a
Demographic data. Overweight was deﬁned as body weight of ≥80 kg in adult
females and ≥100 kg in adult males. Body height was  not documented, therefore
the  BMI  could not be calculated. Since overweight assessment in children would
have required comparison with age-dependent percentile nomograms, no attempt
was made to calculate the proportion of children with overweight.
Demographic attributes Adults Children
N % N %
Total number of subjects 1115 100 125 100
Gender
Male 496 44.5 59 47.2
Female 619 55.5 66 52.8
Age
Young adults (≥16 to <50 years) 704 63.1 N/A N/A
Elderly (≥50 years) 411 36.9 N/A N/A
Weight
Underweight or normal weight 970 87.0 N/A N/A
Overweight 145 13.0 N/A N/A
Number of previous vaccinations
1  132 11.8 12 9.6
2 346 31.0 80 64.0
3 145 13.0 19 15.2
≥4 492 44.1 14 11.2
T
T
t
m
T
Dable 2b
ime  interval since last vaccination in adult subjects. The upper panel shows the propo
he  number of previous vaccinations. The lower panel indicates the minimum time inter
aximum time interval observed in young adults and the elderly.
Interval Number of previous vaccinations
1 2 
≥4 to <15 months 25.0% (n = 33) 2.3% 
≥15 months to <3.5 years 18.1% (n = 24) 33.8%
≥3.5 to <5 years 7.6% (n = 10) 14.7%
≥5  to <10 years 31.1% (n = 41) 28.9%
≥10  years 18.1% (n = 24) 20.2%
Total  n = 132 n = 34
Time intervals [years] exceeded by 50%/25% of the subjects
Young  adults ≥4.9/≥8.5 ≥5.1/
Elderly ≥4.6/≥8.6 ≥4.7/
Maximum interval [years]
Young  adults 18.0 22.3 
Elderly 23.0 20.6 
able 2c
istribution of children/adolescents by number of vaccinations. Due to the small sample 
Number of previous vaccinations
1 2 
Number of subjects (n = 125) 9.6% (n = 12) 64.≥1278 days (1 OR 2 OR  3) AND 4
subjects with 2 vaccinations (64.0%) (Table 2c). The distribution of
gender was not homogeneous in the subgroups (data not shown).
3.2.  Antibody concentration
3.2.1.  Adults
GMC  before catch-up vaccination (Tables 3a and 3b). After 1 or
2 previous vaccinations, the GMC  before the catch-up vaccination
was low in both age groups. With 3 or more previous vaccinations,
the GMC  before the catch-up vaccination was above the putative
seroprotection threshold (≥25 U/ml) in both age groups, but young
adults had a distinctly higher antibody concentration as compared
to the elderly (3 vaccinations subgroup: 61.8 vs. 29.7 U/ml, ≥4 vac-
cinations subgroup: 94.3 vs. 36.1 U/ml).
GMC  after catch-up vaccination (Tables 3a and 3b). The GMC
clearly depends on age and the number of previous vaccinations.
Young adults achieved a substantially higher GMC, ranging from
171.8 U/ml (1 previous vaccination) to 392.8 U/ml (≥4 previous vac-
cinations), as compared to the elderly whose values ranged from
135.8 U/ml (1 previous vaccination) to 196.9 U/ml (≥4 previous
vaccinations).Overall effect of the catch-up vaccination in adult subjects (Fig. 1a).
The RCD curves before catch-up vaccination demonstrate that 1
or 2 previous vaccinations were insufﬁcient to generate long-term
antibody levels above the putative protective threshold whereas a
rtion of subjects in various time intervals since the last vaccination, stratiﬁed by
val being exceeded by 50%/25% of the subjects with the longest intervals, and the
3 ≥4
(n = 8) N/A N/A
 (n = 117) N/A N/A
 (n = 51) 20.0% (n = 29) 29.5% (n = 145)
 (n = 100) 61.4% (n = 89) 55.7% (n = 274)
 (n = 70) 18.6% (n = 27) 14.8% (n = 73)
6 n = 145 n = 492
≥9.0 ≥7.1/≥9.0 ≥6.7/≥8.8
≥8.8 ≥6.0/≥8.1 ≥5.7/≥7.3
16.6 16.5
17.4 18.0
size, no attempt was  made to stratify the subjects by time since last vaccination.
3 ≥4
0% (n = 80) 15.2% (n = 19) 11.2% (n = 14)
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Table 3a
Antibody concentration (GMC in U/ml) in young adults before, and GMC  and putative seroprotection rates after the catch-up vaccination. Data are stratiﬁed by number of
previous  vaccinations. 95% C.I. = 95% conﬁdence interval (lower and upper bound).
No. of prev. vacc. N Antibody concentration before
the catch-up vaccination
Antibody concentration after
the catch-up vaccination
Putative seroprotection rate
after the catch-up vaccination
GMC  95% C.I. GMC  95% C.I. n/N % 95% C.I.
1 87 21.4 [16.3; 28.1] 171.8 [136.6; 216.1] 82/87 94.3% [87.1%; 98.1%]
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p2  231 22.4 [19.5; 25.7] 295
3  86 61.8 [49.0; 77.9] 365
≥4  300 94.3 [83.3; 106.9] 392
rd vaccination added substantially to antibody persistence. After
he catch-up vaccination, individuals with 1 previous vaccination
howed generally lower antibody levels compared to individuals
ith 2, 3, or ≥4 previous vaccinations whose distribution curves
ere comparable.
.2.2. Pediatric population
Table  3c shows the GMC  before and after the catch-up vacci-
ation by number of previous vaccinations. The GMC  before the
atch-up vaccination was similar to those of young adults, with
he exception of the GMC  after 1 previous vaccination which was
onsiderably lower in children (11.2 vs. 21.4 U/ml). The GMC  after
he catch-up vaccination increased with the number of previous
accinations from 259.3 U/ml (1 vaccination) to 435.3 U/ml (≥4 vac-
inations). As compared to young and elderly adults, the GMC  levels
ere higher in children. The RCD curves before and after the catch-
p vaccination (Fig. 1b) are largely similar to the respective curves
n adults.
.3. Putative seroprotection rates (≥25 U/ml) after catch-up
accination
.3.1. Adults
The  majority of subjects with an irregular TBE vaccination
istory achieved antibody levels ≥25 U/ml after the catch-up vac-
ination with FSME-IMMUN (Tables 3a and 3b): After 1 previous
accination, antibody levels ≥25 U/ml were reached by 94.3% of the
oung adults and 93.3% of the elderly. After ≥2 previous vaccina-
ions, antibody concentrations ≥25 U/ml were achieved in >99% of
he young adults and in >96% of the elderly irrespective of the num-
er of previous vaccinations. Young adults accomplished a slightly
igher putative seroprotection rate than the elderly. The putative
eroprotection levels of subjects with an extended time interval of
ore than 10 years since last TBE vaccination (n = 194) were com-
arable to the ones with a shorter vaccination interval (data not
hown).
.3.2. Pediatric population
After  the catch-up vaccination, all except one of the 125 subjects
eached an antibody level of ≥25 U/ml, corresponding to a putative
verall seroprotection rate of 99.2% irrespective of the number of
revious vaccinations (Table 3c).
able 3b
ntibody concentration (GMC in U/ml) in elderly adults before, and GMC and putative se
revious  vaccinations. 95% C.I. = 95% conﬁdence interval (lower and upper bound).
No. of prev. vacc. N Antibody concentration before
the catch-up vaccination
Antibody
the catch
GMC  95% C.I. GMC 
1 45 18.8 [13.9; 25.5] 135.8 
2  115 13.7 [11.8; 16.0] 193.1 
3  59 29.7 [23.0; 38.3] 180.3 
≥4  192 36.1 [31.1; 41.8] 196.9 [262.3; 332.7] 229/231 99.1% [96.9%; 99.9%]
[317.4; 419.8] 86/86 100.0% [95.8%; 100.0%]
[358.6; 430.3] 299/300 99.7% [98.2%; 100.0%]
3.4.  Post vaccination fold increases of antibody concentrations
The GMC  fold increases are strongly dependent on the num-
ber of previous vaccinations (Fig. 2). In adults of both age groups
the highest fold increase was  observed in subjects with 2 previ-
ous vaccinations (14.8-fold in the young adults and 17.1-fold in the
elderly), followed by those with only 1 previous vaccination (9.1-
fold in young adults and 8.3-fold in the elderly). After 3 or more
vaccinations, the fold increase drops to about 4–6 (range: 3.7-fold
to 5.8-fold). Due to the small sample size no such analysis was done
for children.
3.5. Safety
Altogether 6 adverse reactions, 5 in adults and 1 in chil-
dren/adolescents, were reported in temporal relationship with the
catch-up vaccination during the study: Of the adverse reactions
observed in adults, 3 were local reactions at the injection site, 1
was a systemic reaction with ﬂu-like symptoms with onset 2–3
days after immunization, and 1 was a combination of a local reac-
tion and ﬂu-like symptoms 12 h after immunization. The adverse
reaction in the pediatric population was a local reaction at the injec-
tion site. All 6 adverse reactions were classiﬁed as non-serious and
labeled in the summary of product characteristics. The incidence
was 0.48% overall, thereof 0.45% in the adult subpopulation and
0.80% in the pediatric subpopulation.
4. Discussion
With 1115 adult and 125 pediatric subjects analyzed, this is
the largest study on incomplete and/or irregular TBE vaccination
schedules conducted so far and the ﬁrst study which also included
children. The results presented here clearly demonstrate that a
catch-up vaccination with a single dose of FSME-IMMUN was able
to elicit high antibody levels in most of the previously irregularly
TBE vaccinated subjects over a broad age range.
This ﬁnding is corroborated by a recently published study where
FSME-IMMUN was administered in healthy young adults with reg-
ular or delayed TBE vaccination histories and substantial booster
responses were noted in the majority of subjects [10]. However,
whereas our study clearly indicates that the antibody response to a
further dose of TBE vaccine correlates with the number of previous
TBE vaccinations, the booster responses in the study conducted by
roprotection rates after the catch-up vaccination. Data are stratiﬁed by number of
 concentration after
-up vaccination
Putative seroprotection rate
after the catch-up vaccination
95% C.I. n/N % 95% C.I.
[97.0; 190.1] 42/45 93.3% [81.7%; 98.6%]
[159.5; 233.8] 111/115 96.5% [91.3%; 99.0%]
[142.9; 227.4] 58/59 98.3% [90.9%; 100.0%]
[174.6; 222.0] 187/192 97.4% [94.0%; 99.1%]
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Table  3c
Antibody concentration (GMC in U/ml) in children before, and GMC  and putative seroprotection rates after the catch-up vaccination. Data are stratiﬁed by number of previous
vaccinations. 95% C.I. = 95% conﬁdence interval (lower and upper bound).
No. of prev. vacc. N  Antibody concentration before
the catch-up vaccination
Antibody concentration after
the catch-up vaccination
Putative seroprotection rate
after the catch-up vaccination
GMC  95% C.I. GMC  95% C.I. n/N % 95% C.I.
1 12 11.2 [8.5; 14.6] 259.3 [182.3; 368.9] 12/12 100.0% [73.5%; 100.0%]
2  80 25.3 [20.1; 31.7] 342.3 
3  19 61.4 [35.6; 106.0] 321.2 
≥4  14 95.4 [53.4; 170.6] 435.3 
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Fig. 1. (a) Reverse cumulative distribution plot of the overall effect of the catch-
up  vaccination on the TBE antibody response in adults. Shown are the fractions of
adult subjects with speciﬁc TBE antibody concentrations measured by ELISA before
and after the catch-up vaccination stratiﬁed by number of previous vaccinations. (b)
Reverse cumulative distribution plot of the overall effect of the catch-up vaccination
on  the TBE antibody response in children and adolescents. Shown are the fractions
of  children and adolescents with speciﬁc TBE antibody concentrations measured by
ELISA before and after the catch-up vaccination stratiﬁed by number of previous
vaccinations.[281.8; 415.8] 79/80 98.8% [93.2%; 100.0%]
[245.4; 420.5] 19/19 100.0% [82.4%; 100.0%]
[284.4; 666.3] 14/14 100.0% [76.8%; 100.0%]
Askling et al. were independent of the number of previous doses.
This discrepancy could be explained by differences in the study
design and/or the small sample size of various vaccination sub-
groups in the study of Askling et al.
In our study, putatively seroprotective anti-TBE antibody levels
(≥25 U/ml) in response to the catch-up vaccination were reached
by 99–100.0% of the children, 94–100% of the young adults, and
93–98% of the elderly, irrespective of the number of previous TBE
vaccinations. However, the absolute values of the TBE antibody
GMCs after the catch-up FSME-IMMUN vaccination were for all
age groups consistently lower in subjects with only one previous
TBE vaccination as compared to subjects with two or more vac-
cinations, suggesting a shorter period of protection after only one
TBE vaccination. This pattern of increasing antibody responses with
increasing number of previous vaccinations is similar to the pattern
seen during a regular vaccination course [9,13]. Here also, substan-
tial protection can only be expected after the second vaccination. A
third vaccination 5–12 months after the second vaccination is cru-
cial for the completion of the primary vaccination course and for
obtaining a long-lasting antibody response. The pooled serocon-
version rates – deﬁned as ≥126 VIEU/ml (Immunozym ELISA assay)
and a titer of ≥1:10 (neutralization assay) – of all clinical studies
with FSME-IMMUN in subjects with regular vaccination schedules
[13] lie in a similar range as those which we  obtained in subjects
with an irregular vaccination schedule in this study. This ﬁnding
supports the conclusion that, similar to many other inactivated
vaccines, the number of vaccinations is most important for the
mounting of a long-lasting antibody response after a TBE catch-up
or booster dose, regardless of the time intervals between previous
TBE vaccinations. This is in accordance with national recommenda-
tions which emphasize that extended vaccination intervals usually
do not reduce the antibody response to subsequent vaccinations
[14,15].
The GMC  before and after the catch-up vaccination was consis-
tently lower in the elderly as compared to young adults or children.
This observation was also made in the study by Askling et al. and in
many other TBE vaccine studies, and has regularly been attributed
to immunosenescence [11,16–23]. However, recent studies suggest
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hat the quality of antibodies in terms of avidity and functional
ctivity (neutralization assay/ELISA ratio) is not different between
oung adults and the elderly [24]. Furthermore, it has been shown
n our study as well as in other investigations that the fold increase
f the anamnestic antibody response in the elderly is compara-
le to that of young adults [11,25]. This indicates that the quantity
f antibodies is the only difference between young adults and the
lderly which could be explained by the competition model of Rad-
ruch [26,27]. According to this hypothesis the number of survival
iches for long-lived plasma cells in the bone marrow is constant
hroughout life-time. The long-lived plasma cells producing various
ntibody speciﬁcities have to share the limited number of survival
iches. As a subject acquires more and more antibody speciﬁcities
ue to infection or vaccination over the course of a life-time, the
umber of survival niches per antibody speciﬁcity and, as a conse-
uence, also the antibody production will decrease with increasing
ge. Thus, the age-dependent reduction of antibody levels produced
y long-lived plasma cells may  not be a pathological, but rather a
hysiological process, resembling the adaptation to an increasing
umber of antibody speciﬁcities.
The inequality of the group sizes after stratiﬁcation by the num-
er of previous vaccinations possibly reﬂects the real distribution
f the irregularity patterns in the German population. Discontinua-
ion of travel-associated TBE vaccination (subgroup with 2 previous
accinations) or after one or several booster vaccinations (sub-
roup with ≥4 previous vaccinations) is apparently more likely to
ccur than discontinuation after the 1st dose or after completion
f the basic immunization course (subgroup with 3 previous vacci-
ations), thus explaining why the subgroups with 1 or 3 previous
accinations were considerably smaller than those with 2 or ≥4
revious vaccinations. Although each of the two smaller subgroups
ontained more than 130 subjects, the number of subjects drops
elow 100 when it comes to subgroup analysis, e.g. by age. The pedi-
tric population was altogether small (n = 125), resulting in very
mall sample sizes of only 12–19 subjects in the subgroups with 1,
 and ≥4 previous vaccinations. As a consequence, care should be
aken when interpreting the results of the adult population derived
rom small subgroups, and great caution should be exercised when
nterpreting the results of the pediatric population except for the
ubgroup with 2 previous vaccinations.
. Conclusions
From the results of our study it can be concluded that irregular
nd/or incomplete TBE vaccination series should be continued as
f the previous vaccinations had been given according to a regular
chedule. This can be translated into practice as follows:
 1 previous vaccination: Administer the 2nd dose and complete
the  primary vaccination course by a 3rd dose 5–12 months later,
followed  by the 1st booster after 3 years and subsequent booster
doses  every 3 or 5 years (according to age).
 2 previous vaccinations: Administer the 3rd dose to complete
the  primary course, followed by the 1st booster 3 years later and
subsequent  booster doses every 3 or 5 years (according to age).
 3 previous vaccinations: Administer the 1st booster dose fol-
lowed  by subsequent booster doses every 3 or 5 years (according
to  age).
 ≥4 previous vaccinations: Administer the next and subsequent
booster doses every 3 or 5 years (according to age).cknowledgments
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